Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position

被引:10
作者
Bird, David [1 ]
Patel, Chirag [2 ]
Scarsbrook, Andrew F. [2 ]
Cosgrove, Viv [1 ]
Thomas, Emma [3 ]
Gilson, Di [3 ]
Prestwich, Robin J. D. [3 ]
机构
[1] Leeds Teaching Hosp Trust, St Jamess Univ Hosp, Med Phys & Engn, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp Trust, St Jamess Univ Hosp, Radiol & Nucl Med, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp Trust, St Jamess Univ Hosp, Clin Oncol, Leeds, W Yorkshire, England
关键词
Lymphoma; Radiotherapy; Involved site; Clinical target volume; Per-CT; NON-HODGKIN-LYMPHOMA; RADIATION-THERAPY; CANCER-RISK; GUIDELINES; RECOMMENDATIONS; DEFINITION; DISEASE; HEAD;
D O I
10.1016/j.radonc.2017.05.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: involved site radiotherapy clinical target volume (CTV) for lymphoma requires an expansion to account for the absence of radiotherapy treatment-position pre-chemotherapy imaging, which is not widely implemented. This prospective imaging study aims to quantify CTV expansion required for neck radiotherapy. Materials and methods: 10 patients from a prospective single centre imaging study underwent a pre chemotherapy FDG-PET-CT in both the diagnostic and radiotherapy treatment position, and subsequently received neck radiotherapy post-chemotherapy. CTVINRT and CTIdiagpET were delineated on the planning CT, following co-registration of the radiotherapy position PET-CT and side-by-side assessment of diagnostic PET-CT respectively. Results: Intra-observer variability was limited, with delineation of CTVINRT highly reproducible and slightly lower for CTVdiagPET (mean DICE 0.88 and 0.8 respectively). Superiorly, CTVdiagPET varied by -10 to +15 mm from CTVINRT. Inferiorly, CTVdiagPET varied by -18 to +6 mm from CTVINRT. Comparing CTVINRT and CTVdiagPET in the axial plane, the mean DICE was 0.74. Mean sensitivity index was 0.75 (range 0.59-0.91), showing that on average 75% of the CTVINRT was encompassed by the CTVdiagPET Conclusions: In the absence of treatment-position PET-CT, CTV expansion cranially and caudally by 10 mm and 18 mm respectively, along with generous contouring in the axial plane, was required to encompass pre-chemotherapy disease. (c) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:161 / 167
页数:7
相关论文
共 18 条
  • [1] Long-term cause-specific mortality of patients treated for Hodgkin's disease
    Aleman, BMP
    van den Belt-Dusebout, AW
    Klokman, WJ
    van't Veer, MB
    Bartelink, H
    van Leeuwen, FE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3431 - 3439
  • [2] [Anonymous], 2015, LINEAR MIXED MODELS
  • [3] Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
    Cheson, Bruce D.
    Fisher, Richard I.
    Barrington, Sally F.
    Cavalli, Franco
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Lister, T. Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3059 - +
  • [4] Breast Cancer Risk in Female Survivors of Hodgkin's Lymphoma: Lower Risk After Smaller Radiation Volumes
    De Bruin, Marie L.
    Sparidans, Judith
    van't Veer, Mars B.
    Noordijk, Evert M.
    Louwman, Marieke W. J.
    Zijlstra, Josee M.
    van den Berg, Hendrik
    Russell, Nicola S.
    Broeks, Annegien
    Baaijens, Margreet H. A.
    Aleman, Berthe M. P.
    van Leeuwen, Flora E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4239 - 4246
  • [5] MEASURES OF THE AMOUNT OF ECOLOGIC ASSOCIATION BETWEEN SPECIES
    DICE, LR
    [J]. ECOLOGY, 1945, 26 (03) : 297 - 302
  • [6] Second malignancy risk associated with treatment of Hodgkin's lymphoma:: meta-analysis of the randomised trials
    Franklin, J.
    Pluetschow, A.
    Paus, M.
    Specht, L.
    Anselmo, A. -P.
    Aviles, A.
    Biti, G.
    Bogatyreva, T.
    Bonadonna, G.
    Brillant, C.
    Cavalieri, E.
    Diehl, V.
    Eghbali, H.
    Ferme, C.
    Henry-Amar, M.
    Hoppe, R.
    Howard, S.
    Meyer, R.
    Niedzwiecki, D.
    Pavlovsky, S.
    Radford, J.
    Raemaekers, J.
    Ryder, D.
    Schiller, P.
    Shakhtarina, S.
    Valagussa, P.
    Wilimas, J.
    Yahalom, J.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (12) : 1749 - 1760
  • [7] Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
    Girinsky, Theodore
    van der Maazen, Richard
    Specht, Lena
    Aleman, Berthe
    Poortmans, Philip
    Lievens, Yolande
    Meijnders, Paul
    Ghalibafian, Mithra
    Meerwaldt, Jacobus
    Noordijk, Evert
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 79 (03) : 270 - 277
  • [8] Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?
    Girinskya, Theodore
    Ghalibafian, Mithra
    Bonniaud, Guillaume
    Baya, Aziz
    Magne, Nicolas
    Ferreira, Ivaldo
    Lumbroso, Jean
    [J]. RADIOTHERAPY AND ONCOLOGY, 2007, 85 (02) : 178 - 186
  • [9] Expert Radiation Oncologist Interpretations of Involved-Site Radiation Therapy Guidelines in the Management of Hodgkin Lymphoma
    Hoppe, Bradford S.
    Hoppe, Richard T.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (01): : 40 - 45
  • [10] Recommendations for the Use of Radiotherapy in Nodal Lymphoma
    Hoskin, P. J.
    Diez, P.
    Williams, M.
    Lucraft, H.
    Bayne, M.
    [J]. CLINICAL ONCOLOGY, 2013, 25 (01) : 49 - 58